1. Home
  2. SPRO vs SCYX Comparison

SPRO vs SCYX Comparison

Compare SPRO & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • SCYX
  • Stock Information
  • Founded
  • SPRO 2013
  • SCYX 1999
  • Country
  • SPRO United States
  • SCYX United States
  • Employees
  • SPRO N/A
  • SCYX N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPRO Health Care
  • SCYX Health Care
  • Exchange
  • SPRO Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • SPRO 40.5M
  • SCYX 40.9M
  • IPO Year
  • SPRO 2017
  • SCYX 2014
  • Fundamental
  • Price
  • SPRO $0.62
  • SCYX $0.94
  • Analyst Decision
  • SPRO Buy
  • SCYX
  • Analyst Count
  • SPRO 4
  • SCYX 0
  • Target Price
  • SPRO $5.00
  • SCYX N/A
  • AVG Volume (30 Days)
  • SPRO 113.5K
  • SCYX 82.8K
  • Earning Date
  • SPRO 05-13-2025
  • SCYX 05-20-2025
  • Dividend Yield
  • SPRO N/A
  • SCYX N/A
  • EPS Growth
  • SPRO N/A
  • SCYX N/A
  • EPS
  • SPRO N/A
  • SCYX N/A
  • Revenue
  • SPRO $47,977,000.00
  • SCYX $3,746,000.00
  • Revenue This Year
  • SPRO N/A
  • SCYX $460.12
  • Revenue Next Year
  • SPRO N/A
  • SCYX $253.87
  • P/E Ratio
  • SPRO N/A
  • SCYX N/A
  • Revenue Growth
  • SPRO N/A
  • SCYX N/A
  • 52 Week Low
  • SPRO $0.51
  • SCYX $0.73
  • 52 Week High
  • SPRO $1.72
  • SCYX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 41.34
  • SCYX 47.33
  • Support Level
  • SPRO $0.64
  • SCYX $0.93
  • Resistance Level
  • SPRO $0.75
  • SCYX $1.00
  • Average True Range (ATR)
  • SPRO 0.05
  • SCYX 0.07
  • MACD
  • SPRO -0.01
  • SCYX -0.00
  • Stochastic Oscillator
  • SPRO 21.63
  • SCYX 7.60

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: